David Russler-Germain, MD/PhD
@dgermain21
Followers
4K
Following
42K
Media
438
Statuses
50K
Oncology Instructor @SitemanCenter @WUSTLmed | lymphoma/leukemia researcher @LabFehniger | all views 100% my own
St. Louis, MO
Joined January 2009
Pretty much everyone who knows me knows I'm a big fan of bispecific antibodies for B-NHL. For a summary of key landmarks in this space, emerging evidence and lessons from recent clinical trials, and exciting new directions, check out our review:.
frontiersin.org
Several key advances in the treatment of B-cell non-Hodgkin lymphoma (B-NHL) over the past two decades have strategically exploited B-cell lineage markers su...
5
12
95
RT @JoachimSchork: Many researchers overlook or misinterpret statistical assumptions. Misunderstanding these assumptions can lead to using….
0
32
0
RT @joe_pickrell: I was looking for a good visualization of lifetime risk of disease for 'important' mutations, and really like this one on….
0
6
0
Agreed. America needs better access to and reimbursement for primary care. But our deficiencies in primary care aren’t the main drivers of disappointing life expectancy statistics.
This really cuts to the core of healthcare debates. what do we prioritize from our healthcare system? Do we want us to keep us “healthy,” guiding our life choices and managing chronic diseases? Or do we want a system that is ready to take care of major illnesses when they pop.
0
0
1
RT @tangming2005: 1/ Most biologists fail at computation not because it’s hard—.but because they start in the wrong place. Here’s the roadm….
0
61
0
RT @lymphomahub: 🚨 NEWS 🚨.@GovCanHealth grants market authorization for glofitamab + GemOx, for the treatment of adult patients with R/R DL….
0
2
0
RT @the_asci: ASCI Early-Career Award Nominations are open: Emerging-Generation + Young Physician-Scientist Awards. High-level recognition….
0
6
0
RT @LGMartelotto: Very proud of these two! . Kellie Wise (@Kellieiswise) Anna Pascual-Reguant. @DrJasPlummer @hoheyn . @cnag_eu @StJudeRese….
nature.com
Nature Reviews Genetics - In this Tools of the Trade article, Kellie Wise and Anna Pascual-Reguant introduce STAMP (single-cell transcriptomics analysis and multimodal profiling), which harnesses...
0
8
0
RT @FrancescoMaura4: Excited to share our new paper, out today on @NatureGenet where we use 421 #WGS to reconstruct the evolutionary histo….
0
32
0
RT @tangming2005: You can save millions $ for your organization if everyone follows best practices to fill in a spreadsheet. Do simple thi….
0
4
0
Love this. But should we all show our cards, revealing where our practice differs and bring receipts? :).
#Hematology #Lymphomas: @myESMO Clinical Practice Guideline for diagnosis, treatment and follow-up - @Annals_Oncology #lymsm
1
0
2
RT @DrChoueiri: Important @US_FDA Guidance for Clinical trials —no real surprises here. Some points to emphasize:. -Stats needs to be CLEAR….
0
44
0
RT @Eddie_Cliff: @oncology_bg The crossover comments from FDA are disappointing on multiple levels - appropriate crossover is also not conf….
0
3
0
RT @oncology_bg: The latest FDA Guidance emphasizes OS to rule out harm. It’s better than nothing but OS should be viewed as an efficacy en….
0
4
0
RT @NicoGagelmann: Practice-changing study in hematology!. Arsenic Trioxide and All-Trans Retinoic Acid Combination Therapy for the Treatme….
ascopubs.org
PURPOSEThe phase III APOLLO trial prospectively compared the efficacy of arsenic trioxide (ATO) in combination with all-trans retinoic acid (ATRA) regimen (ATRA and ATO [ATRA-ATO]) plus low-dose...
0
58
0
RT @VincentRK: Academic medicine is bleeding talent. The best experts are counting to retire or switch careers at an alarming rate. It’s….
0
33
0
RT @nickmmark: Why - in the year 2025 - are we *STILL* subjecting ICU patients to frequent painful fingersticks when continuous glucose mon….
0
43
0
RT @JCO_ASCO: Remission Assessment by Circulating Tumor DNA in Large B-Cell Lymphoma. Co-authored by @AshAlizadeh, @RoschewskiMD, @DrJasonW….
ascopubs.org
PurposeLarge B-cell lymphomas (LBCL) are curable, but patients with residual disease after therapy invariably experience progression. Ultrasensitive methods to detect circulating tumor DNA (ctDNA) as...
0
10
0
RT @majorajay: Survival after incidental vs symptomatic FL:.- 908 pts, 29% incidental.- incidental: more early stage & normal LDH.- no diff….
0
18
0